Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Liquid handling

New solution for low-volume dispensing presented at SLAS 2026

Analytik Jena will be presenting new automation solutions for laboratory workflows at the SLAS 2026 International Conference & Exhibition (February 7–11). A particular highlight is the launch…

News • Gastric multi-regional assembloid

Lab-grown mini-stomachs to boost understanding of rare diseases

A new type of lab-grown organoid that mimics the behaviour of a human stomach could boost the understanding of rare gastric diseases, researchers say.

News • Laboratory Information Management System

Blood transfusion service receives LIMS upgrade

The Blood Transfusion service at Aneurin Bevan University Health Board (ABUHB) has implemented Clinisys WinPath LIMS, marking the first deployment of this system in Wales.